New anticoagulant drugs for atrial fibrillation. Feasibility and necessity of monitoring;Neue antikoagulanzien bei vorhofflimmern: Ist ein monitoring möglich und notwendig?

Herz

Volumn 37, Issue 4, 2012, Pages 378-383

  Madlener, K ^a   Hamm, C ^b  

^a KERCKHOFF HEART CENTER   (Germany)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Dabigatran; Monitoring; Rivaroxaban

Indexed keywords

ANTIVITAMIN K; DABIGATRAN; NEW DRUG; RIVAROXABAN;

ANTICOAGULATION; ARTICLE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG DETERMINATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; FEASIBILITY STUDY; HEART ATRIUM FIBRILLATION; HUMAN; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; QUANTITATIVE ANALYSIS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS; STROKE; VITAMIN K;

EID: 84864290224     PISSN: 03409937     EISSN: 16156692     Source Type: Journal    
DOI: 10.1007/s00059-012-3618-9     Document Type: Article

References (32)

1. Ageno W, Gallus AS, Wittkowsky A et al (2012) Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e44S-e88S
2. Weitz JI, Eikelboom JW, Samama MM (2012) New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e120S-e151S
3. Steffel J, Braunwald E (2011) Novel oral anticoagulants: focus on stroke prevention and treatment of venous thromboembolism. Eur Heart J 32(16):1968-1976
4. Schulman S (1994) Quality of oral anticoagulant control and treatment in Sweden: Duration of Anticoagulation (DURAC) Trial Study Group. J Intern Med 236:143-115
5. Pressemitteilung BfArM; 16. November 2011: Gerinnungshemmer Pradaxa: Kausalzusammenhang mit deutschen Todesfällen kann als sicher angenommen werden - Sicherheitsmaßnahmen bereits in der Umsetzung
6. Pressemitteilung EAM; 18. November 2011: European Medicines Agency updates on safety of Pradaxa.
7. Bounameaux H, Reber G (2010) New oral antithrombotics: a need for laboratory monitoring. J Thromb Haemost 8:627-630
8. Mismetti P, Laporte S (2010) New oral antithrombotics: a need for laboratory monitoring. J Thromb Haemost 8:621-626
9. Ansell J, Hirsh J, Dalen J et al (2001) Managing oral anticoagulant therapy. Chest 119(1 Suppl):22S-38S (Pubitemid 32154193)
10. Fuster V, Rydén LE, Cannom DS et al (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation 114(7):e257-e354
11. Rost S, Fregin A, Ivaskevicius V et al (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427(6974):537-541 (Pubitemid 38209110)
12. Rieder MJ, Reiner AP, Gage BF et al (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352(22):2285-2293 (Pubitemid 40740552)
13. Ansell JE (2000) The quality of anticoagulation management. Arch Intern Med 160:967-973
14. Bussey HI, Respond RM, Quandt CM, Clark GM (1989) The safety and effectiveness of long-term warfarin therapy in an anticoagulation clinic. Pharmacotherapy 9:214-219 (Pubitemid 19229528)
15. Garcia DA, Trevor P, Baglin TP et al (2012) Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e24S-e43S
16. Kearon C, Ginsberg JS, Julian JA et al; Fixed-Dose Heparin (FIDO) Investigators (2006) Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 296(8):935-942 (Pubitemid 44285370)
17. Al Dieri R, Alban S, Béguin S, Hemker HC (2006) Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight. J Thromb Haemost 4:83-88
18. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ (1991) Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 78(9):2337-2343
19. Leizorovicz A, Bara L, Samama MM, Haugh MC (1993) Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. Haemostasis 23(Suppl 1):89-98 (Pubitemid 23116280)
20. Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF et al (1994) Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group. Thromb Haemost 71(6):698-702 (Pubitemid 24177954)
21. Lim W, Dentali F, Eikelboom JW, Crowther MA (2006) Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 144:673-684 (Pubitemid 46780653)
22. Paolucci F, Frasa H, Van Aarle F et al (2003) Two sensitive and rapid chromogenic assays of fondaparinux sodium (Arixtra) in human plasma and other biological matrices. Clin Lab 49(9-10):451-460 (Pubitemid 37266109)
23. Klaeffling C, Piechottka G, Daemgen-von Brevern G et al (2006) Development and clinical evaluation of two chromogenic substrate methods for monitoring fondaparinux sodium. Ther Drug Monit 28(3):375-381 (Pubitemid 44314925)
24. Di Nisio M, Middeldorp S, Büller HR (2005) Direct thrombin inhibitors. N Engl J Med 353(10):1028-1040 (Pubitemid 41262337)
25. Stangier J, Rathgen K, Stähle H et al (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64(3):292-303 (Pubitemid 47283865)
26. Liesenfeld KH, Schäfer HG, Troconiz IF et al (2006) Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol 62:527-537 (Pubitemid 44571573)
27. Lindahl TL, Baghaei F, Blixter IF et al (2011) Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 105(2):371-378
28. van Ryn J, Stangier J, Haertter S et al (2010) Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103(6):1116-1127
29. Liesenfeld KH, Lehr T, Dansirikul C et al (2011) Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 9(11):2168-2175
30. Laux V, Perzborn E, Kubitza D, Misselwitz F (2007) Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor. Semin Thromb Hemost 33:515-523 (Pubitemid 47105742)
31. Hillarp A, Baghaei F, Fagerberg Blixter I et al (2011) Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 9(1):133-139
32. Lindhoff-Last E, Samama MM, Ortel TL et al (2010) Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit 32:673-679